

ASX RELEASE

Ellex Medical Lasers Limited (ASX:ELX)

Adelaide, Australia

Date: 30 August 2018

Release: Immediate

Topic: Ellex response on recent MIGS device withdrawal



Adelaide, Australia, 30 August 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today responded on the implications for its Ellex iTrack™ business of the announcement yesterday by Novartis of the withdrawal from sale of the *CyPass Microstent* minimally invasive glaucoma surgery (MIGS) device.

The decision by Novartis highlights the fast-changing nature of the market for the supply of MIGS devices.

The *CyPass Microstent* is 6mm long device that is permanently placed in a patient's eye for treating mild to moderate primary open angle glaucoma. This product has been voluntarily withdrawn from sale following the release of data on patients in whom a *CyPass Microstent* had been implanted for 5 years.

The Ellex iTrack™ surgical system is used to perform a minimally invasive surgical procedure on patients with primary open angle glaucoma. During this procedure the Ellex iTrack™ catheter is temporarily inserted, typically for a few minutes or less, into Schlemms Canal to dilate and clear the canal and thereby promote a restorative healing response which lowers eye pressure. As a matter of course we continue to monitor our clinical data. As Ellex iTrack™ is not a permanent implant, we are optimistic about the continued safety of our product

Ellex believes that the Ellex iTrack™ surgical system is a gentle, restorative, low risk, leave-nothing-behind approach which is an ideal primary surgical therapy for patients with glaucoma. All other implantable MIGS devices of various designs are permanently placed in the eye.

ABOUT ELLEX

Ellex designs, develops, manufactures and sells innovative products that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Fremont, Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

For additional information about Ellex and its products, please visit www.ellex.com

For further information on Ellex please contact:

Tom Spurling, CEO
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes, SA, 5095
W +61 8 7074 8293 | M +61 417 818 658
tspurling@ellex.com

Mark Lindh
W +61 8 8232 8800 | M +61 414 551 361
mlindh@ellex.com

Maria Maieli, CFO & Company Secretary
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes, SA, 5095
W +61 8 7074 8200
mmaieli@ellex.com